Imunon (IMNN)

• Market cap: $11.3M
• 1 day: 0.3%
• 5 days: -10.03%
• 1 month: -4.6%
• 3 months: -26.06%
• 6 months: -49.85%
• Year to date: -15.95%
• 1 year: -72.03%
• 5 years: -98.83%
• 10 years: -99.91%
• Sector: Healthcare
• Industry: Biotechnology

About: Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Employees: 25